This is a new service – your feedback will help us to improve it.
Using this page · Individualise medicines monitoring

This medicines monitoring page has been written using publications and expert opinion. It is designed to save clinician time, but not replace professional responsibility. When using this page you should: ensure an individualised monitoring plan is developed in partnership with the patient and take account of any locally agreed advice and guidance.

Before starting


  • Baseline
    • Estimated glomerular filtration ratefor galantamine and rivastigmine only
    • Liver function tests
    • Serum potassiumfor galantamine

LFTs and hepatic function: respond if abnormal


Caution in mild to moderate impairment.
Adjust dose as per BNF advice.


Caution in moderate impairment; avoid in severe impairment (Child-Pugh score greater than 9).
Adjust dose as per BNF advice.


Caution in hepatic impairment.
Adjust dose as per BNF advice.

Renal function: respond if abnormal


Avoid if eGFR less than 9 mL/minute/1.73 m2


Caution in renal impairment

Potassium: respond if abnormal


Caution in hyperkalaemia or hypokalaemia

Ongoing once stable


  • Periodically
    • Weightfor rivastigmine and galantamine, since decreased appetite possible


Advice to patients for galantamine

Advise patients and their carers to be aware of the potential for serious skin reactions related to galantamine. These include Stevens-Johnson syndrome, erythema multiforme, and acute generalized exanthematous pustulosis.
Advise patients to report any skin rash. Stop galantamine at the first appearance of any skin rash.


Enquiries about this page

Contact us if you have any enquiries about the drug monitoring information on this page.